About Nimbus Therapeutics
Nimbus Therapeutics is a company based in Cambridge (United States) founded in 2009.. Nimbus Therapeutics has raised $685 million across 12 funding rounds from investors including Pfizer, Schrödinger and Citadel. The company has 81 employees as of December 31, 2022. Nimbus Therapeutics offers products and services including TYK2 inhibitor, HPK1 inhibitor, and ACC inhibitor. Nimbus Therapeutics operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Aclaris Therapeutics, among others.
- Headquarter Cambridge, United States
- Employees 81 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Nimbus Discovery Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$685 M (USD)
in 12 rounds
-
Latest Funding Round
$210 M (USD), Series F
Sep 06, 2023
-
Investors
Pfizer
& 20 more
-
Employee Count
81
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Nimbus Therapeutics
Nimbus Therapeutics offers a comprehensive portfolio of products and services, including TYK2 inhibitor, HPK1 inhibitor, and ACC inhibitor. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Inhibitor for immune-mediated diseases through clinical development.
Inhibitor for oncology applications in drug discovery.
Inhibitor targeting liver diseases via partnerships.
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Nimbus Therapeutics
Nimbus Therapeutics has successfully raised a total of $685M across 12 strategic funding rounds. The most recent funding activity was a Series F round of $210 million completed in September 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 12
- Last Round Series F — $210.0M
-
First Round
First Round
(15 Apr 2010)
- Investors Count 21
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2023 | Amount | Series F - Nimbus Therapeutics | Valuation | SR One , Google Ventures | |
| Sep, 2022 | Amount | Series E - Nimbus Therapeutics | Valuation | SV Health Investors , Bain Capital Life Sciences | |
| Jul, 2021 | Amount | Series D - Nimbus Therapeutics | Valuation | BVF Partners |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Nimbus Therapeutics
Nimbus Therapeutics has secured backing from 21 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Pfizer, Schrödinger and Citadel. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A biotechnology venture capital firm investing in innovative science.
|
Founded Year | Domain | Location | |
|
Corporate backed venture capital fund investing in multiple sectors
|
Founded Year | Domain | Location | |
|
Venture capital firm investing in life science and biotechnology sectors
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Nimbus Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Nimbus Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Nimbus Therapeutics Comparisons
Competitors of Nimbus Therapeutics
Nimbus Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Aclaris Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Novel dermatologic therapies are developed for skin conditions.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Nimbus Therapeutics
Frequently Asked Questions about Nimbus Therapeutics
When was Nimbus Therapeutics founded?
Nimbus Therapeutics was founded in 2009 and raised its 1st funding round 1 year after it was founded.
Where is Nimbus Therapeutics located?
Nimbus Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Who is the current CEO of Nimbus Therapeutics?
Jeb Keiper is the current CEO of Nimbus Therapeutics.
Is Nimbus Therapeutics a funded company?
Nimbus Therapeutics is a funded company, having raised a total of $685M across 12 funding rounds to date. The company's 1st funding round was a Series D of $105M, raised on Apr 15, 2010.
How many employees does Nimbus Therapeutics have?
As of Dec 31, 2022, the latest employee count at Nimbus Therapeutics is 81.
What does Nimbus Therapeutics do?
Nimbus Therapeutics was founded in 2009 in Cambridge, United States, within the biotechnology sector. Targeted therapeutics are developed by the company for cancer, metabolic, and inflammatory diseases. The lead candidate is directed at acetyl-CoA carboxylase (ACC) for treating nonalcoholic steatohepatitis (NASH). An additional candidate, an IRAK4 inhibitor, is pursued to address Tyk2 and KRas pathways involved in immune signaling. Operations focus on advancing these programs through research and development.
Who are the top competitors of Nimbus Therapeutics?
Nimbus Therapeutics's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
What products or services does Nimbus Therapeutics offer?
Nimbus Therapeutics offers TYK2 inhibitor, HPK1 inhibitor, and ACC inhibitor.
Who are Nimbus Therapeutics's investors?
Nimbus Therapeutics has 21 investors. Key investors include Pfizer, Schrödinger, Citadel, RA Capital, and GSK.